San Francisco -- Patients with moderate to severe psoriasis can receive efalizumab (Anti-CD11a) continually with no increased toxicity for approximately one year, an ongoing open-label trial shows.
The Weekly Roundup: March 20-24
The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques
Lebrikizumab Demonstrates Promising Results in Atopic Dermatitis
The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice
Highlights from AAD 2023
Vitamin D Supplements During Pregnancy May Reduce Eczema in Infants
2 Clarke Drive Cranbury, NJ 08512